This funding opportunity is to support research grant(s) to advance the state of knowledge, develop novel techniques, agents, methodologies, models, or applications that could have a significant impact on drug hypersensitivity research. This funding mechanism is designed to further research in drug allergy/hypersensitivity for individuals with a current or future focus in drug hypersensitivity research. Priority will be given to junior faculty and those without current NIH funding. For the purpose of this opportunity vaccines are not considered drugs, and applications that focus on vaccine reactions will NOT be considered for this award.
Amount
This two-year award will provide for direct costs (salary, lab expenses, etc.) ranging from $50,000 - $150,000 (dispersed to the awardees institution in four equal payments). Award term is July 1, 2027 to June 30, 2029. Funds may not be used for institutional indirect costs.
Selection
The following entities will be involved in the selection of awardees:
1. AAAAI Grant Review Committee
2. AAAAI Board of Directors
Terms
Once the award is granted, the following requirements will need to be met to ensure that the award will
continue throughout the 2-year award cycle:
1. An annual written progress report describing research efforts and other career development aspects, as well as a summary of the allocation of the received funds (Due July 1 of each award year).
2. Acknowledgement of the AAAAI support when giving presentations or in any publications that result
from the research conducted and sponsored by the award.
3. Must be a member of the AAAAI during the award term.
This is the fundamental predictor.
Strong projects should directly address areas such as:
The strongest applications make the connection to allergy/immunology patient care and scientific advancement immediately apparent. AAAAI's stated mission is to advance knowledge and practice in allergy, asthma and immunology for optimal patient care.
Reviewers assess the quality and potential impact of the proposed research.
A strong proposal should answer:
Projects with a clear connection between scientific discovery and meaningful clinical benefit are particularly compelling.
Innovation is a major success factor.
Competitive proposals may involve:
For example, the 2026 Faculty Development Awardees include research on hidden splice variants in inborn errors of immunity, T-cell/alveolar-macrophage interactions in lung inflammation, and mast-cell progenitors as biomarkers of food allergy—all highly focused mechanistic or translational questions.
A promising idea must be supported by a rigorous approach.
Strong applications should provide:
AAAAI's Grant Review Committee evaluates both the quality and potential impact of proposed research and research-related activities.
The AAAAI Foundation's Faculty Development Award has a particularly clear objective: support excellent research that can contribute to the prevention and cure of asthma, allergic, and immunologic disease.
Therefore, strong projects should ideally show potential to:
This is one of the most important AAAAI Foundation-specific predictors.
The Faculty Development Award is specifically designed to develop junior faculty into independent investigators.
A strong early-career applicant should demonstrate:
The Foundation reports that 55 of 57 major awardees have continued careers in allergy/immunology, illustrating the strong career-development emphasis of the program.
For the Faculty Development Award, applicants must have a current mentor.
A strong mentor should provide:
The proposal should make clear that the applicant is progressing from mentored research toward independent research leadership.
This is an explicit AAAAI Foundation priority, not merely a generic consideration.
The Foundation states that it is especially interested in health-equity research in allergy/immunology and research promoting diversity and inclusivity. It also encourages applications from minority investigators and researchers from diverse geographic areas.
Strong projects may address:
For career-development awards, institutional support is critical.
A competitive applicant should have:
The AAAAI Foundation's Bridge Award application, for example, requires the department/division head to confirm the applicant's full-time faculty appointment, future institutional path, space and funding commitment, and protected time.
This is an especially strong AAAAI Foundation predictor.
The Foundation reports that its initial support has been followed by nearly $143 million in federal grants to its award recipients since 1993.
Its Award to Sustain Research Excellence (Bridge Award) is explicitly designed to strengthen a revised or planned five-year R01 application and requires applicants to explain how the Foundation funding will increase the competitiveness of the R01.
Therefore, a strong application should show:
AAAAI funding → preliminary/strengthening data → NIH application → independent research program
Applicants must meet the following requirements to be eligible:
1. Be board certified in allergy/immunology by the American Board of Allergy and Immunology (ABAI) or
hold the equivalent certification from the Royal College of Physicians and Surgeons of Canada (RCPSC).
2. At the time of Letter of Intent (August 14), applicant must be at or below the level of Associate
Professor (or equivalent).
3. Primary faculty appointment must be in the discipline of allergy/immunology.
4. One of the following degrees:
• MD
• MD, PhD
• DO
• DO, PhD
5. Citizen or permanent resident of the United States or Canada.
6. A member of the AAAAI.
Eligible Countries:
Sponsor Institute/Organizations: American Academy of Allergy, Asthma & Immunology
Sponsor Type: Corporate/Non-Profit
Address: 555 East Wells Street, Suite 1100, Milwaukee
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Oct 12, 2026
Oct 12, 2026
$150,000
Affiliation: American Academy of Allergy, Asthma & Immunology
Address: 555 East Wells Street, Suite 1100, Milwaukee
Website URL: file:///C:/Users/rvija/Downloads/PRDESC10782.pdf
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.